FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2094328193> ?p ?o ?g. }

• W2094328193 endingPage "7" @default.
• W2094328193 startingPage "1" @default.
• W2094328193 abstract "Chronic lymphocytic leukemia is the most common leukemia in the United States. It is a slowly progressive disease, with an 82% five-year survival rate. The treatment strategies are highly individualized with patients in the early and stable stages typically not requiring treatment. However, those with progressive or clinically advanced disease will require treatment. Cytotoxic drugs, such as the alkylating agents, purine nucleoside antagonists, and immunotherapeutic agents, have been the mainstay of chemotherapeutic treatment in CLL. However, given the lack of therapeutic specificity, these medications (especially older ones) have limited tolerability due to side effects. In this paper, we will discuss the data on the use of phosphatidylinositol 3 kinase inhibitor Idelalisib in the management of patients with chronic lymphocytic leukemia. The preclinical and clinical data thus far demonstrate that Idelalisib produces a dramatic and durable response in patients with chronic lymphocytic leukemia and without causing significant toxicity. Moving forward, the ongoing clinical trials will help address the various questions currently being raised regarding the long-term application and safety of Idelalisib. With greater clinical experience following more widespread use of Idelalisib, we will be able to determine the optimal combination therapies in treatment-naïve and relapsed/refractory patients, resulting in more individualized therapeutic strategies for patients with chronic lymphocytic leukemia." @default.
• W2094328193 created "2016-06-24" @default.
• W2094328193 creator A5005530070 @default.
• W2094328193 creator A5026497057 @default.
• W2094328193 creator A5054562480 @default.
• W2094328193 creator A5067716442 @default.
• W2094328193 date "2014-04-01" @default.
• W2094328193 modified "2023-09-22" @default.
• W2094328193 title "Idelalisib for the Treatment of Chronic Lymphocytic Leukemia" @default.
• W2094328193 cites W1493876987 @default.
• W2094328193 cites W1506715112 @default.
• W2094328193 cites W1966207848 @default.
• W2094328193 cites W1980466127 @default.
• W2094328193 cites W1983395516 @default.
• W2094328193 cites W1984147944 @default.
• W2094328193 cites W2008937679 @default.
• W2094328193 cites W2012671933 @default.
• W2094328193 cites W2025234369 @default.
• W2094328193 cites W2025786205 @default.
• W2094328193 cites W2027971058 @default.
• W2094328193 cites W2034623756 @default.
• W2094328193 cites W2057370954 @default.
• W2094328193 cites W2060254656 @default.
• W2094328193 cites W2061929146 @default.
• W2094328193 cites W2066564017 @default.
• W2094328193 cites W2074269911 @default.
• W2094328193 cites W2078948501 @default.
• W2094328193 cites W2081103640 @default.
• W2094328193 cites W2091664866 @default.
• W2094328193 cites W2098166849 @default.
• W2094328193 cites W2104235597 @default.
• W2094328193 cites W2116815941 @default.
• W2094328193 cites W2131826846 @default.
• W2094328193 cites W2134645992 @default.
• W2094328193 cites W2137334689 @default.
• W2094328193 cites W2141858983 @default.
• W2094328193 cites W2142099365 @default.
• W2094328193 cites W2167692982 @default.
• W2094328193 cites W2171443164 @default.
• W2094328193 cites W2187874122 @default.
• W2094328193 cites W2411959550 @default.
• W2094328193 cites W262475294 @default.
• W2094328193 doi "https://doi.org/10.1155/2014/931858" @default.
• W2094328193 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4003830" @default.
• W2094328193 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25093123" @default.
• W2094328193 hasPublicationYear "2014" @default.
• W2094328193 type Work @default.
• W2094328193 sameAs 2094328193 @default.
• W2094328193 citedByCount "5" @default.
• W2094328193 countsByYear W20943281932015 @default.
• W2094328193 countsByYear W20943281932016 @default.
• W2094328193 countsByYear W20943281932020 @default.
• W2094328193 crossrefType "journal-article" @default.
• W2094328193 hasAuthorship W2094328193A5005530070 @default.
• W2094328193 hasAuthorship W2094328193A5026497057 @default.
• W2094328193 hasAuthorship W2094328193A5054562480 @default.
• W2094328193 hasAuthorship W2094328193A5067716442 @default.
• W2094328193 hasBestOaLocation W20943281931 @default.
• W2094328193 hasConcept C126322002 @default.
• W2094328193 hasConcept C143998085 @default.
• W2094328193 hasConcept C197934379 @default.
• W2094328193 hasConcept C203014093 @default.
• W2094328193 hasConcept C2777938653 @default.
• W2094328193 hasConcept C2778375690 @default.
• W2094328193 hasConcept C2778461978 @default.
• W2094328193 hasConcept C2778714382 @default.
• W2094328193 hasConcept C2779260929 @default.
• W2094328193 hasConcept C2779338263 @default.
• W2094328193 hasConcept C2779878957 @default.
• W2094328193 hasConcept C2780653079 @default.
• W2094328193 hasConcept C71924100 @default.
• W2094328193 hasConceptScore W2094328193C126322002 @default.
• W2094328193 hasConceptScore W2094328193C143998085 @default.
• W2094328193 hasConceptScore W2094328193C197934379 @default.
• W2094328193 hasConceptScore W2094328193C203014093 @default.
• W2094328193 hasConceptScore W2094328193C2777938653 @default.
• W2094328193 hasConceptScore W2094328193C2778375690 @default.
• W2094328193 hasConceptScore W2094328193C2778461978 @default.
• W2094328193 hasConceptScore W2094328193C2778714382 @default.
• W2094328193 hasConceptScore W2094328193C2779260929 @default.
• W2094328193 hasConceptScore W2094328193C2779338263 @default.
• W2094328193 hasConceptScore W2094328193C2779878957 @default.
• W2094328193 hasConceptScore W2094328193C2780653079 @default.
• W2094328193 hasConceptScore W2094328193C71924100 @default.
• W2094328193 hasLocation W20943281931 @default.
• W2094328193 hasLocation W20943281932 @default.
• W2094328193 hasLocation W20943281933 @default.
• W2094328193 hasLocation W20943281934 @default.
• W2094328193 hasOpenAccess W2094328193 @default.
• W2094328193 hasPrimaryLocation W20943281931 @default.
• W2094328193 hasRelatedWork W2014078906 @default.
• W2094328193 hasRelatedWork W2106082064 @default.
• W2094328193 hasRelatedWork W2125229272 @default.
• W2094328193 hasRelatedWork W2256822827 @default.
• W2094328193 hasRelatedWork W2294347960 @default.
• W2094328193 hasRelatedWork W2301427507 @default.
• W2094328193 hasRelatedWork W2339877219 @default.
• W2094328193 hasRelatedWork W2343108749 @default.

• next